Table 3.

Clinical and preclinical data related to anti-FGL1 therapy

Number	Year	Type of tumor	Human/mouse/cell line	Name of FGL1 antibody	Conclusions	References
1	2021	PDAC	Cell lines	FGL1 antibody, (Proteintech)	Anti-FGL1 was associated with lipid metabolism and cell growth in PDAC	[115]
2	2021	HCC	Cell lines	FGL1 antibody, (Proteintech)	Anti-FGL1 eliminated resistance to sorafenib in HCC cells	[116]
3	2020	NSCLC	Cell lines	ab197357 (Abcam)	Anti-FGL1 increased the sensitivity of NSCLC cells to gefitinib	[114]
4	2019	Murine colon adenocarcinoma	Cell lines and mouse model	Anti-mouse FGL1 (clone 177R4)	Both anti-FGL1 and anti-LAG3 mAbs significantly controlled the growth of tumors derived from the MC38 murine colon that were inoculated into syngeneic C57BL/6 mice	[50]
5	2019	Murine liver cell	Cell lines and mouse model		Both anti-FGL1 and anti-LAG3 mAbs significantly controlled the growth of tumors derived from established Hepa1-6 murine liver cell lines that were inoculated into syngeneic C57BL/6 mice

HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma